Behavioral Pharmacology of Antipsychotics

  • H. Kreiskott
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)


It is the task of behavioral pharmacology to find and to differentiate substance actions in animals and in man by observation or instrumental analysis of spontaneous individual and social behavior, of the antagonistic and/or synergistic influence on stimulus and/or drug-induced behavioral changes as well as of effects on learning and memorizing capacity.


Tardive Dyskinesia Maternal Behavior Golden Hamster Neuroleptic Drug Excitation Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson, H.A., Evans, L.T.: Lysergic acid diethylamide (LSD 25): II. Psychobiological effects on the Siamese fighting fish. Science 120, 990–991 (1954)PubMedGoogle Scholar
  2. Ackenheil, M., Hippius, H., Matussek, N.: Ergebnisse der biochemischen Forschung auf dem Schizophrenie-Gebiet. Nervenarzt 49, 634–649 (1978)PubMedGoogle Scholar
  3. Andén, N.-E., Dahlström, A., Fuxe, K., Larsson, K.: Functional role of the nigro-neostriatal dopamine neurons. Acta Pharmacol. Toxicol. (Kbh.) 24, 263–274 (1966 a)Google Scholar
  4. Andén, N.-E., Fuxe, K., Larsson, K.: Effect of large mesencephalic-diencephalic lesions on the noradrenalin, dopamine and 5-hydroxytryptamine neurons of the central nervous system. Experientia 22, 842–843 (1966 b)PubMedGoogle Scholar
  5. Andén, N.-E., Rubenson, A., Fuxe, K., Hökfelt, T.: Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19, 627–629 (1967)PubMedGoogle Scholar
  6. Angst, J., Battegay, R., Bente, D., Berner, P., Broeren, W., Cornu, F., Dick, P., Engelmeier, M.-P., Heimann, H., Heinrich, K., Helmchen, H., Hippius, H., Pöldinger, W., Schmidlin, P., Schmitt, W., Weis, P.: Das Dokumentations-System der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMP). Arzneim. Forsch. 19, 399–405 (1969)Google Scholar
  7. Ashcroft, G.W., Eccleston, D., Waddell, J.L.: Recognition of amphetamine addicts. Br. Med. J. 1, 57 (1965)PubMedGoogle Scholar
  8. Asper, H., Baggiolini, M., Bürki, H.R., Lauener, H., Ruch, W., Stille, G.: Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur. J. Pharmacol. 22, 287–294 (1973)PubMedGoogle Scholar
  9. Aston, R., Sekino, E., Greifenstein, F.E.: Quantitation of drug effects upon conditioned avoidance behavior in the rat. Toxicol. Appl. Pharmacol. 4, 393–401 (1962)PubMedGoogle Scholar
  10. Baldessarini, R.J., Tarsy, D.: Tardive dyskinesia. In: Psychopharmacology. A generation of progress. Lipton, M.A., Di Mascio, A., Killam, K.F. (eds.), pp. 993–1004. New York: Raven Press 1978Google Scholar
  11. Banerjee, U., Burks, T.F., Feldberg, W., Goodrich, CA.: Temperature effects of reserpine injected into the cerebral ventricles of rabbits and cats. J. Physiol. 197, 221–231 (1968)PubMedGoogle Scholar
  12. Bartholini, G.: Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J. Pharm. Pharmacol. 28, 429–433 (1976)PubMedGoogle Scholar
  13. Bein, H.J.: Zur Pharmakologie des Reserpin, eines neuen Alkaloids aus Rauwolfia serpentina Benth. Experientia 9, 107–110 (1953)PubMedGoogle Scholar
  14. Berchtold, P., Hinssen, M., Irmscher, K.: Tardive Dyskinesie, ein wenig bekanntes extrapyramidales Syndrom als Folge der Therapie mit Neuroleptika. Dtsch. Med. Wochenschr.99, 420–421 (1974)PubMedGoogle Scholar
  15. Bergmann, F., Chaimovitz, M., Pasternak, V., Ramu, A.: Compulsive gnawing in rats after implantation of drugs into the ventral thalamus. A contribution to the mechanism of morphine action. Br. J. Pharmacol. 57, 197–205 (1974)Google Scholar
  16. Berry, P.A., Lister, R.E., Beattie, I.A.: Oxypertine and primate behaviour. Postgrad. Med. J. 48, Suppl. 4, 11–14(1972)PubMedGoogle Scholar
  17. Bhargava, K.P., Chandra, O.: Anti-emetic activity of phenothiazines in relation to their chemical structure. Br. J. Pharmacol. 21, 436–440 (1963)Google Scholar
  18. Blösch, M.: Über die Wirkung einiger Phenothiacine auf das Verhalten von freilebenden Silber-möven (Larus a. argentatus Pontopp). Psychopharmacologia 25, 380–387 (1972)PubMedGoogle Scholar
  19. Boissier, J.R., Simon, P.: Dissociation de deux composantes dans le comportement d’investigation de la souris. Arch. Int. Pharmacodyn. Thér. 147, 372–387 (1964)Google Scholar
  20. Borison, R.L., Havdala, H.S., Diamond, B.I.: Chronic phenylethylamine stereotypy in rats: A new animal model for schizophrenia. Life Sci. 21, 117–122 (1977)PubMedGoogle Scholar
  21. Boshka, S.E., Weissman, M.C., Thor, D.H.: A technique for inducing aggression in rats utilizing morphine withdrawal. Psychol. Rec. 16, 541–543 (1966)Google Scholar
  22. Boyd, E.M.: Chlorpromazine tolerance and physical dependence. J. Pharmacol. 128, 75–78 (1960)Google Scholar
  23. Brady, J.V., Nauta, W.J.H.: Subcortical mechanism in emotional behavior: affective changes following septal and habenular lesions in the albino rat. J. Comp. Physiol. Psychol. 46, 339–346 (1953)PubMedGoogle Scholar
  24. Brady, J.V., Nauta, W.J.H.: Subcortical mechanism in emotional behavior: the duration or affective changes following septal and habenular lesions in the albino rat. J. Comp. Physiol. Psychol. 48, 412–420 (1955)PubMedGoogle Scholar
  25. Bürki, H.R., Eichenberger, E., Sayers, A.C., White, T.C.: Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopsychiatr. Neuropsychopharmacol. 8, 115–121 (1975)Google Scholar
  26. Burt, D.R., Creese, I., Snyder, S.H.: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196, 326–328 (1977)PubMedGoogle Scholar
  27. Chari-Bitron, A.A., Chari-Bitron, A.: Estimation of low chlorpromazine concentrations by surfacing and sinking reaction of minnows (Gambusia affinis). Psychopharmacologia 18, 407–411 (1970)PubMedGoogle Scholar
  28. Coscia, L., Causa, P., Giuliani, E., Nunziata, A.: Pharmacological properties of new neuroleptic compounds. Arzneim. Forsch. 25, 1436–1442 (1975)Google Scholar
  29. Costall, B., Naylor, R.J.: Neuroleptic and non-neuroleptic catalepsy. Arzneim. Forsch. 23, 674–683 (1973)Google Scholar
  30. Costall, B., Naylor, R.J., Olley, J.E.: Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur. J. Pharmacol. 18, 83–94 (1972)PubMedGoogle Scholar
  31. Courvoisier, S., Fournel, J., Ducrot, R., Kolsky, M., Koetschet, P.: Propriétés pharmacologi-ques du chlorhydrate de chloro-3-(diméthylamino-3′-propyl)-10-phénothiazine (4.560 R.P.). Arch. Int. Pharmacodyn. Thér. 92, 305–361 (1953)PubMedGoogle Scholar
  32. Courvoisier, S., Ducrot, R., Julou, L.: Nouveaux aspects expérimentaux de l’activité centrale des dérivés de la phénothiazine. In: Psychotropic drugs. Garattini, S., Ghetti, V. (eds.), pp. 373–391. Amsterdam: Elsevier 1957Google Scholar
  33. Cytawa, J., Kutulas, G.: Influence of chlorpromazine on emotional hyperreactivity resulting from septal forebrain injury. Psychopharmacologia 27, 389–392 (1972)PubMedGoogle Scholar
  34. Davanzo, J.P.: Observations related to drug-induced alterrations in aggressive behaviour. In: Aggressive behaviour. Garattini, S., Sigg, E.B. (eds.), pp. 263–272. Amsterdam: Excerpta Medica 1969Google Scholar
  35. Debus, G.: Wirkung von Psychopharmaka und zugrundeliegende theoretische Vorstellungen. Pharmakopsychiatr. Neuropsychopharmacol. 10, 109–118 (1977)Google Scholar
  36. Delay, J., Deniker, T., Harl, J.M.: Utilisation en que psychiatrique d’une phénothiazine d’action centrale sélective. Ann. Med. Psychol. Fr. 110, 112–117 (1952)Google Scholar
  37. Delini-Stula, A.: Increased sensitivity to neuroleptics in rats with lesions of the central nervous system. Psychopharmacologia 26, 84–90 (1972)PubMedGoogle Scholar
  38. Domino, E.F., Hudson, R.D., Zografi, G.: Substituted phenothiazines: Pharmacology and chemical structure. In: Drugs affecting the central nervous system. Burger, A. (ed.), pp. 327–397. New York: Marcel Dekker 1968Google Scholar
  39. Doyle, C., Shimizu, A., Himwich, H.E.: Effects of chronic administration of some psychoactive drugs on EEG arousal on rabbit. Int. J. Neuropharmacol. 7, 87–95 (1968)PubMedGoogle Scholar
  40. Dreyfuss, J., Beer, B., Devine, D.D., Roberts, B.F., Schreiber, E.C.: Fluphenazine-induced parkinsonism in the baboon: Pharmacological and metabolic studies. Neuropharmacology 11, 223–230 (1972)PubMedGoogle Scholar
  41. Echols, S.D., Ursillo, R.C.: Significance of species differences: Rotational models. In: Animal models in psychiatry and neurology. Hanin, I., Usdin, E. (eds.), pp. 27–34. Oxford: Perga-mon Press 1977Google Scholar
  42. Eliasson, M., Meyerson, B.J.: Comparison of the action of lysergic acid diethylamide and apomorphine on the copulatory response in the female rat. Psychopharmacology 49, 301–306 (1976)PubMedGoogle Scholar
  43. Ellinwood, E.H., Kilbey, M.M.: Chronic stimulant intoxication models of psychosis. In: Animal models in psychiatry and neurology. Hanin, I., Usdin, E. (eds.), pp. 61–74. Oxford: Per-gamon Press 1977Google Scholar
  44. Ellinwood, E.H., Sudilovsky, A., Nelson, L.M.: Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am. J. Psychiatry 130, 1088–1093 (1973)PubMedGoogle Scholar
  45. Emley, G.S., Hutchinson, R.R.: Similar and selective actions of chlorpromazine, chlordiazep-oxide, and nicotine on shock-produced aggressive and anticipatory motor responses in the squirrel monkey. Proceedings, 79 th Annual Convention, APA, pp. 759–760 (1971)Google Scholar
  46. Engelmeier, M.-P.: Das Gesamtwirkungsspektrum enzephalotroper Medikamente und Scine Bedeutung für die psychiatrische Pharmakotherapie. In: Begleitwirkungen und Mißerfolge der psychiatrischen Pharmakotherapie. Kranz, H., Heinrich, K. (eds.), pp. 4–12. Stuttgart: Thieme 1964Google Scholar
  47. Ernst, A.M., van Andel, H., Charbon, G.A.: Beruht die experimentelle Katatonie durch Tryp-tamin auf einer Verdrängung des 5-Hydroxytryptamin? Psychopharmacologia 2, 425–435 (1961)PubMedGoogle Scholar
  48. Ezrin-Waters, C., Seeman, P.: Tolerance to haloperidol catalepsy. Eur. J. Pharmacol. 41, 321 – 327 (1977)PubMedGoogle Scholar
  49. Fielding, S., Lal, H.: Behavioral actions of neuroleptics. In: Neuroleptics and schizophrenia. Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 10,, 91–128. New York: Plenum Press 1978Google Scholar
  50. Fischer, H.: Vergleichende Pharmakologie von Überträgersubstanzen in tiersystematischer Darstellung. In: Handbuch der experimentellen Pharmakologie, Vol. XXVI. Berlin, Heidelberg, New York: Springer 1971Google Scholar
  51. Flügel, F.: Über medikamentös erzeugte parkinsonähnliche Zustandsbilder. Med. Klin. 50, 634–635 (1955)Google Scholar
  52. Francis, N., Marley, E., Stephenson, J.D.: Effects of spiperone on self-stimulation and other activities of the mongolian gerbil. Br. J. Pharmacol. 63, 43–49 (1978)PubMedGoogle Scholar
  53. Fraňková, S.: Drug-induced changes in the maternal behavior of rats. Psychopharmacology 53, 83–87 (1977)PubMedGoogle Scholar
  54. Giono-Barber, H., Giono-Barber, P., Bertuletti, G.: Methode d’essai des substances psychotropes sur le comportement de domination du Singe Cynocephale (Papio papio). Compt. Rend. Soc. Biol. 164, 199–203 (1970)Google Scholar
  55. Greenblatt, D.J., Shader, R.I.: Rational use of psychotropic drugs. In: Drug therapy reviews. Miller, R.R., Greenblatt, D.J. (eds.), Vol. 1, pp. 59–72. New York: Masson 1977Google Scholar
  56. Gunne, L.M., Bárány, S.: Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 50, 237–240 (1976)PubMedGoogle Scholar
  57. Haase, H.J.: Therapie mit Psychopharmaka und anderen psychotropen Medikamenten. Düsseldorf: Janssen 1966Google Scholar
  58. Haase, H.J.: Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten. Stuttgart: Schattauer 1977Google Scholar
  59. Heinrich, K.: Zur Bedeutung der Stammesgeschichte des menschlichen Erlebens und Verhaltens für Neurologie und Psychopathologie. Homo 16, 65–77 (1965)Google Scholar
  60. Heinrich, K.: Die psychiatrische Frühklinik bei psychotischen Störungen. Therapiewoche 27, 6450–6459 (1977)Google Scholar
  61. Hippius, H., Matussek, N.: Bemerkungen zur Biologischen Psychiatrie. Nervenarzt 49, 650–653 (1978)PubMedGoogle Scholar
  62. Hoebel, B.G.: Feeding: Neural control of intake. Am. Rev. Physiol. 33, 533–568 (1971)Google Scholar
  63. Hoffmeister, F.: Negative reinforcing properties of some psychotropic drugs in drug-naive rhesus monkeys. J. Pharmacol. Exp. Ther. 192, 468–477 (1975)PubMedGoogle Scholar
  64. Hoffmeister, F., Wuttke, W.: On the actions of psychotropic drugs on the attack- and aggressive-defensive behaviour of mice and cats. In: Aggressive behaviour. Garattini, S., Sigg, E.B. (eds.), pp. 273–280. Amsterdam: Excerpta Medica 1969Google Scholar
  65. Huber, G.: Langzeittherapie der Schizophrenie in der Praxis. Med. Welt 28, 213–217 (1977)Google Scholar
  66. Hughes, R.N., Syme, L.A., Syme, G J.: Open-field behaviour in sheep following treatment with the neuroleptics azaperone and acetylpromazine. Psychopharmacology 52, 107–109 (1977)PubMedGoogle Scholar
  67. Hunt, H.F.: Some effects of drugs on classical (Type S) conditioning. Ann. N.Y. Acad. Sci. 65, 258–267 (1956)PubMedGoogle Scholar
  68. Hunt, H.F.: Some effects of meprobamate on conditioned fear and emotional behavior. Ann. N.Y. Acad. Sci. 67,712–123 (1957)PubMedGoogle Scholar
  69. Irwin, S.: The value of animal experimentation. In: Psychopharmacology frontiers. Kline, N.S. (ed.). Boston: 1957Google Scholar
  70. Irwin, S.: Differential tolerance development to the avoidance and locomotor suppressant actions of perphenazine and chlorpromazine. Pharmacologist 3, 75 (1961)Google Scholar
  71. Irwin, S.: Influence of experimental variables on the rate of tolerance development to chlorpromazine and perphenazine. Fed. Proc. 21, 419 (1962)Google Scholar
  72. Irwin, S.: Drug screening and evaluation of new compounds in animals. In: Animal and clinical pharmacologic techniques in drug evaluation. Nodine, J.H., Siegler, P.E. (eds.), Vol. 1, pp. 36–54. Chicago: Year Book Medical 1964Google Scholar
  73. Irwin, S., Konohi, R.G.: Single and repeat dose effects of imipramine and chlorpromazine in man. Psychopharmacol. Bull. 7, 23–24 (1971)PubMedGoogle Scholar
  74. Irwin, S., Kinohi, R., Van Sloten, M., Workman, M.P.: Drug effects on distress-evoked behavior in mice: methodology and drug class comparisons. Psychopharmacologia 20, 172–185 (1971)PubMedGoogle Scholar
  75. Itil, T.M.: Quantitative analysis of “motor pattern” in schizophrenia. In: Schizophrenia current concepts and research. Siva Sankar, D.V. (ed.), Hicksville, N.Y.: PJD Publications Ltd. (year of publication unknown)Google Scholar
  76. Janssen, P.A.J.: Vergleichende pharmakologische Daten über sechs neue basische 4’-Fluorobu-tyrophenon-Derivate. Arzneim. Forsch. 11, 932–938 (1961)Google Scholar
  77. Janssen, P.A.J., van Bever, W.F.M.: Structure-activity relationships of the butyrophenones and diphenylbutylpiperidines. In: Neuroleptics and schizophrenia. Handbook of Psychopharmacology, Iversen, C.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 10, pp. 1–35. New York: Plenum Press 1978Google Scholar
  78. Janssen, P.A.J., Jageneau, A.H., van Proosdij-Hartzema, E.G., De Jongh, D.K.: The pharmacology of a new potent analgesic R 951 2-[N(4-carbethoxy-4-phenyl)-piperidino] propio-phenone HCl. Acta Physiol. Pharmacol. Neerl. 7, 373–402 (1958)PubMedGoogle Scholar
  79. Janssen, P.A.J., Jageneau, A.H., Niemegeers, C.J.E.: Effects of various drugs on isolation-induced fighting behavior of male mice. J. Pharmacol. Exp. Ther. 129, 471–475 (1960 a)PubMedGoogle Scholar
  80. Janssen, P.A.J., Niemegeers, C.J.E., Schellekens, K.H.L.: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data. Arzneim. Forsch. 15, 104–117(1965)Google Scholar
  81. Karli, P.: The norway rat’s killing response to the white mouse: an experimental analysis. Behaviour 10, 81–103 (1956)Google Scholar
  82. Karli, P.: Action de l’amphétamine et de la chlorpromazin sur l’agressivité interspécifique rat-souris. Compt. Rend. Soc. Biol. 152, 1796–1798 (1958)Google Scholar
  83. Karli, P., Vergnes, M., Didiergeorges, F.: Rat-mouse interspecific aggressive behaviour and its manipulation by brain ablation and by brain stimulation. In: Aggressive behaviour. Garattini, S., Sigg, E.B. (eds.), pp. 47–55. Amsterdam: Excerpta Medica 1969Google Scholar
  84. Kehne, J.H., Sorenson, CA.: The effects of pimozide and phenoxybenzamine pretreatments on amphetamine and apomorphine potentiation of the acoustic startle response in rats. Psychopharmacology 58, 137–144 (1978)PubMedGoogle Scholar
  85. Janssen, P.A.J., Jageneau, A.H.M., Schellekens, K.H.L.: Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. Psychopharmacologia 1, 389–392 (1960 b)PubMedGoogle Scholar
  86. Janssen, P.A.J., Niemegeers, C.J.E., Schellekens, K.H.L., Verbruggen, F.J., Van Nueten, J.M.: The pharmacology of Dehydrobenzperidol, a new potent and short acting neuroleptic agent chemically related to Haloperidol. Arzneim. Forsch. 13, 205–211 (1963)Google Scholar
  87. Keiper, R.R.: Drug effects on canary stereotypies. Psychopharmacologia 16, 16–24 (1969)PubMedGoogle Scholar
  88. Kinnard, W.J., Carr, C.J.: A preliminary procedure for the evaluation of central nervous system depressants. J. Pharmacol. Exp. Ther. 121, 354–361 (1957)PubMedGoogle Scholar
  89. Kinnard, W.J. Jr., Watzman, N.: Techniques utilized in the evaluation of psychotropic drugs on animal activity, J. Pharm. Sci. 55, 995–1012 (1966)Google Scholar
  90. Kjellberg, B., Randrup, A.: Partial restoration by a neuroleptic (spiramide) of items of grooming behaviour suppressed by Amphetamine. Arch. Int. Pharmacodyn. Thér. 210, 61–66 (1974)PubMedGoogle Scholar
  91. Kneip, P.: Kletter-Trieb und Kletter-Test. Arch. Int. Pharmacodyn. Thér. 126, 238–245 (1960)PubMedGoogle Scholar
  92. Kosheleva, O.V.: Reserpine action on the arrest reaction following stimulation of the caudate nucleus in cats. Farmakol. Toksikol. 38, 650–652 (1975)PubMedGoogle Scholar
  93. Kostowski, W., Czlonkowski, A.: The activity of some neuroleptic drugs and amphetamine in normal and isolated rats. Pharmacology 10, 82–87 (1973)PubMedGoogle Scholar
  94. Kreiskott, H.: Einfluß von Pharmaka auf das Beutefangverhalten der Ratte. Arch. Exp. Path. Pharmak. 245, 54 (1963 a)Google Scholar
  95. Kreiskott, H.: Die experimentelle Erzeugung von Starrezuständen an Octopus vulgaris durch Kataleptica (Bulbocapnin und Phenothiazine). Arch. Exp. Path. Pharmak. 246, 24 (1963 b)Google Scholar
  96. Kreiskott, H.: Zur Verhaltensforschung im Rahmen der Psychopharmakologie. Medizin und Chemie 7, 57–78 (1963 c)Google Scholar
  97. Kreiskott, H.: Verhaltensänderungen an Tieren unter dem Einfluß von antipsychotischen Drogen. Diskussion. In: Bente, D., Bradley, P.B. (eds.), Neuropsychopharmacology 4, 115 – 117. Amsterdam: Elsevier 1965 aGoogle Scholar
  98. Kreiskott, H.: Kataleptische Zustände von Octopus vulgaris nach Butyrylperazin und Bulbocapnin. In: Bente, D., Bradley, P.B. (eds.), Neuropsychopharmacology 4, 172. Amsterdam: Elsevier 1965 bGoogle Scholar
  99. Kreiskott, H.: Some comments on the killing response behavior of the rat. In: Aggressive behaviour. Garattini, S., Sigg, E.B. (eds.). Amsterdam: Excerpta Medica 56–58, 1969Google Scholar
  100. Kreiskott, H.: Verhaltensänderungen durch psychotrope Substanzen bei Versuchstieren. Arz-neim. Forsch. 24, 1294–1297 (1974a)Google Scholar
  101. Kreiskott, H.: Einführung zum Thema Längsschnittprofile von Psychopharmakawirkungen. Arzneim. Forsch. 24, 974–976 (1974 b)Google Scholar
  102. Kreiskott, H.: Erregungszustände von Tier und Mensch. Stuttgart: Fischer 1979Google Scholar
  103. Kreiskott, H., Vater, W.: Verhaltensstudien am Goldhamster unter dem Einfluß zentral wirksamer Substanzen. Arch. Exp. Path. Pharmakol. 236, 100 (1959)Google Scholar
  104. Krnjević, H., Videk, M.: A new method of testing CNS-active compounds (hole test). Psycho-pharmacologia 10, 308–315 (1967)Google Scholar
  105. Laborit, H.: Potenzierte Narkose und künstlicher Winterschlaf. Arch. Exp. Pathol. Pharmakol. 222, 41–58 (1954)Google Scholar
  106. Lal, H., Numan, R.: Blockade of morphine- withdrawal body shakes by haloperidol. Life Sci. 18, 163–168 (1976)PubMedGoogle Scholar
  107. Lal, H., Hynes, M.D.: Effectiveness of butyrophenones and related drugs in narcotic withdrawal. In: Proceedings Collegium International Neuro-Psychopharmacology. Deniker, P., Radouco-Thomas, G., Villeneuve, A. (eds.), Vol.1, pp. 289–295. New York: Pergamon Press 1978Google Scholar
  108. Lal, H., Defeo, J.J., Thut, P.: Effect of amphetamine on pain induced aggression. Comm. Be-hav. Biol. 1, 333–336 (1968)Google Scholar
  109. Lal, H., Defeo, J.J., Pittermann, A., Patel, G., Baumel, I.: Effects of prolonged social deprivation or enrichment on neuronal sensitivity for CNS depressants and stimulant. In: Drug addiction. Singh, J.M., Miller, L.H., Lal, H. (eds.), Vol. 1, pp. 255–266. New York: Futura 1972Google Scholar
  110. Lal, H., Gianutsos, G., Puri, S.K.: Comparison of narcotic analgesics with neuroleptics on behavior measures of dopaminergic act. Life Sci. 17, 29–34 (1975)PubMedGoogle Scholar
  111. Lal, H., Marky, M., Fielding, S.: Effect of neuroleptic drugs on mouse jumping induced by 1-dopa in amphetamine treated mice. Neuropharmacology 15, 669–671 (1976)PubMedGoogle Scholar
  112. Leyhausen, P.: Zur Naturgeschichte der Angst. Politische Psychologie 6, (1967). In: Antriebe tierischen und menschlichen Verhaltens. Lorenz, K., Leyhausen, P. (eds.). München: Pieper 1968Google Scholar
  113. Leyhausen, P.: Verhaltensstudien an Katzen 3 rd ed. Berlin, Hamburg: Parey 1973Google Scholar
  114. Lim, R.K.S., Rink, K.G., Glass, H.G., Soaje-Echague, E.: A method for the evaluation of cumulation and tolerance by the determination of acute and subchronic median effective doses. Arch. Int. Pharmacodyn. Thér. 130, 336–353 (1961)PubMedGoogle Scholar
  115. Ljungberg, T., Ungerstedt, U.: Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanism of action. Psychopharmacology 56, 239–247 (1978)PubMedGoogle Scholar
  116. Loew, D.M.: The prediction of sedative potency of neuroleptics. In: The neuroleptics. Bobon, D.P., Janssen, P.A.J., Bobon, J. (eds.), pp. 47–50. Basel: Karger 1970Google Scholar
  117. Malick, J.B., Sofia, R.D., Goldberg, M.E.: A comparative study of the effects of selected psychoactive agents upon three lesion-induced models of aggression in the rat. Arch. Int. Phar-macodyn. Thér. 181, 459–465 (1969)Google Scholar
  118. McKinney, W.T., Young, L.D., Suomi, S.J., Davis, J.M.: Chlorpromazine treatment of disturbed monkeys. Arch. Gen. Psychiatry 29, 490–494 (1973)PubMedGoogle Scholar
  119. Menge, H.G., Brand, U.: Zur Differenzierung der Wirkung kataleptogener Stoffe. Arzneim. Forsch. 28, 1506–1507 (1978)Google Scholar
  120. Mercier, J., Dessaigne, S.: Influence exercée par quelques drogues psycholeptiques sur le comportement du scorpion (Adroctonus australis Hector). Compt. Rend. Soc. Biol. 164, 341 – 344 (1970)Google Scholar
  121. Moller Nielsen, L, Fjalland, B., Pedersen, V., Nymark, M.: Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia 34, 95–104 (1974)Google Scholar
  122. Moore, K.E., Kelly, P.H.: Biochemical pharmacology of mesolimbic and mesocortical dopaminergic neurons. In: Psychopharmacology. A generation of progress. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.), pp. 221–234. New York: Raven Press 1978Google Scholar
  123. Munkvad, I.: Neuroleptics in the treatment of schizophrenia. In: The neuroleptics. Bobon, D.P., Janssen, P.A.J., Bobon, J. (eds.), pp. 44–47. Basel: Karger 1970Google Scholar
  124. Niemegeers, C.J.E., Janssen, P.A.J.: Differential antagonism to amphetamine-induced oxygen consumption and agitation by psychoactive drugs. In: Antidepressants. Fielding, S., Lal, H. (eds.), pp. 125–141. New York: Futura 1975Google Scholar
  125. Norton, S.: Behavioral patterns as a technique for studying psychotropic drugs. In: Psychotropic drugs. 73–82. Garattini, S., Ghetti, V. (eds.). Amsterdam: Elsevier 1957Google Scholar
  126. Nymark, M.: Apomorphine provoked stereotypy in the dog. Psychopharmacologia 26, 361–368 (1972)PubMedGoogle Scholar
  127. Oberst, F.W., Crook, J.W.: Behavioral, physical, and pharmacodynamic effects of haloperidol in dogs and monkeys. Arch. Int. Pharmacodyn. Thér. 167, 450–464 (1967)PubMedGoogle Scholar
  128. Opitz, K.: Anorexigene Phenylalkylamine und Serotoninstoffwechsel. Arch. Pharmakol. exp. Pathol. 259, 56–65 (1967)Google Scholar
  129. Ploog, D.: Verhaltensforschung und Psychiatric In: Forschung und Praxis. Gruhle, H.W., Jung, R., Mayer-Gross, W., Müller, M. (eds.), Psychiatrie der Gegenwart, Vol. I/IB, pp. 291–443. Verlin, Göttingen, Heidelberg, New York: 1964Google Scholar
  130. Raitt, J.R., Nelson, J.W., Tye, A.: Effect of chlorpromazine on septal hyperactivity in the rat. Br. J. Pharmacol. 17, 473–478 (1961)Google Scholar
  131. Remane, A.: Die Grundlagen des natürlichen Systems, der vergleichenden Anatomie und der Phylogenetik. Leipzig: Geest & Portwig 1952Google Scholar
  132. Robbins, T.W.: A critique of the methods available for the measurement of spontaneous motor activity. In: Principles of behavioral pharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 7, pp. 37–82. New York: Plenum Press 1977Google Scholar
  133. Sackett, G.P.: Abnormal behavior in laboratory-reared rhesus monkeys. In: Abnormal behavior in animals. Fox, M.W. (ed.), pp. 293–331. Philadelphia: Saunders 1968Google Scholar
  134. Sandberg, F.: A comparative quantitative study of the central depressant effect of seven clinically used phenothiazine derivatives. Arzneim. Forsch. 9, 203–206 (1959)Google Scholar
  135. Schelkunov, E.L.: Adrenergic effect of chronic administration of neuroleptics. Nature 214, 1210–1212 (1967)PubMedGoogle Scholar
  136. Schmidt, W., Apfelbach, R.: Psychopharmakologische Beeinflußung des Beutefangverhaltens beim Frettchen (Putorius furo L.). Psychopharmacology 51, 147–152 (1977)PubMedGoogle Scholar
  137. Senault, B.: Comportement d’agressivité intraspécifïque induit par l’apomorphine chez le rat. Psychopharmacologia 18, 271–287 (1970)PubMedGoogle Scholar
  138. Sheard, M.H.: The role of drugs in precipitating or inhibiting human aggression. Psychopharmacology 13, 23–25 (1977)Google Scholar
  139. Simpson, G.M., Lee, J.H.: A ten-year review of antipsychotics. In: Psychopharmacology. A generation of progress. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.), pp. 1131–1137. New York: Raven Press 1978Google Scholar
  140. Sofia, R.D.: Effects of centrally active drugs on four models experimentally-induced aggression in rodents. Life Sci. 8, 705–716 (1969)PubMedGoogle Scholar
  141. Sovner, R., DiMascio, A.: Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Psychopharmacology. A generation of progress. Lipton, M.A., DiMascio, A, Killam, K.F. (eds.), pp. 1021–1032. New York: Raven Press 1978Google Scholar
  142. Spengler, J., Waser, P.: Der Einfluß verschiedener Pharmaka auf den Futterkonsum von Albino-Ratten im akuten Versuch. Arch. Exp. Pathol. Pharmakol. 237, 171–185 (1959)Google Scholar
  143. Stawarz, R.J., Hill, H., Robinson, S.E., Setler, P., Dingell, J.V., Sulser, F.: On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. Psychopharmacologia 43, 125–130 (1975)PubMedGoogle Scholar
  144. Stille, G.: Zur Pharmakologie katatonigener Stoffe. Aulendorf: Editio Cantor 1971Google Scholar
  145. Stille, G.: Entwicklung von Psychopharmaka. Dtsch. Ärztebl. 45, 3249–3251 (1974)Google Scholar
  146. Stille, G., Lauener, H.: Die Wirkung von Neuroleptika im chronischen pharmakologischen Experiment. Vortrag 2. Zentraleur. Symposion, Neuropsychopharmacol. and Pharmaco-psychiatr. Split 1971Google Scholar
  147. Sulser, F., Robinson, S.E.: Clinical implications of pharmacological differences among antipsychotic drugs (with particular emphasis on biochemical central synaptic adrenergic mechanism). In: Psychopharmacology. A generation of progress. Lipton, M.A., DiMascio, A., Killiam, K.F. (eds.), pp. 943–954. New York: Raven Press 1978Google Scholar
  148. Symoens, J.: Vorbeugen und Heilung von Aggressivität und Streß bei Schweinen durch das Neuroleptikum Azaperone. Dtsch. Tierärztl. Wochenschr. 77, 144–148 (1970)PubMedGoogle Scholar
  149. Taeschler, M., Cerletti, A.: Zur Pharmakologie psychoaktiver Wirkstoffe. Münch. Med. Wochenschr. 102, 1000–1005 (1960)Google Scholar
  150. Tagliamonte, A., Fratta, W., Gessa, G.L.: Aphrodisiac effect of L-Dopa and Apomorphine in male sexually sluggish rats. Experientia 30, 381–382 (1974)PubMedGoogle Scholar
  151. Tedeschi, D.H.: Techniques for evaluating neuroleptics: comments on their mechanism of action. In: Animal and clinical pharmacologic techniques in drug evaluation. Siegler, P.E., Moyer, J.H. (eds.), Vol.2, pp. 297–304. Chicago: Year Book Medical 1967Google Scholar
  152. Tedeschi, D.H., Tedeschi, R.E., Fellows, E.J.: The effects of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs. J. Pharmacol. Exp. Ther. 126, 223–232 (1959 a)PubMedGoogle Scholar
  153. Tedeschi, R.E., Tedeschi, D.H., Mucha, A., Cock, L., Mattis, P.A., Fellows, E.J.: Effects of various centrally acting drugs on fighting behavior of mice. J. Pharmacol. Exp. Ther. 125, 28–34 (1959 b)PubMedGoogle Scholar
  154. Tedeschi, D.H., Fowler, P.J., Miller, R.B., Macko, E.: Pharmacological analysis of footshock-induced fighting behavior. In: Aggressive behaviour. Garattini, S., Sigg, E.B. (eds.), pp. 245–252. Amsterdam: Excerpta Medica 1969Google Scholar
  155. Theobald, W., Büch, O., Delina-Stula, A., Eigenmann, R., Levin, P.: Pharmakologische Untersuchungen zur Wirkung von Neuroleptica am Tier nach einmaliger und wiederholter Applikation. Arzneim. Forsch. 18, 1491–1495 (1968)Google Scholar
  156. Ther, L., Vogel, G., Werner, P.: Zur pharmakologischen Differenzierung und Bewertung der Neuroleptika. Arzneim. Forsch. 9, 351–354 (1959)Google Scholar
  157. Thompson, T.: Aggressive behavior of Siamese fighting fish. In: Aggressive behavior. Garattini, S., Sigg, E.B. (eds.), pp. 15–31. Amsterdam: Excerpta Medica 1969Google Scholar
  158. Tripod, J., Bein, H.J., Meier, R.: Characterization of central effects of serpasil (reserpin, a new alkaloid of rauwolfia serpentina B.) and their antagonistic reactions. Arch. Int. Pharmaco-dyn. Ther. 96, 406–425 (1954)Google Scholar
  159. Ungerstedt, U.: 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5, 107–110 (1968)PubMedGoogle Scholar
  160. Valzelli, L., Garattini, S.: Biochemical and behavioral changes induced by isolation in rats. Neuropharmacology 11, 17–22 (1972)PubMedGoogle Scholar
  161. Valzelli, L., Giacalone, E., Garattini, S.: Pharmacological control of aggressive behavior in mice. Eur. J. Pharmacol. 2, 144–146 (1967)PubMedGoogle Scholar
  162. Van Rossum, J.M.: Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors. In: The neuroleptics. Bobon, D.P., Janssen, P.A.J., Bobon, J. (eds.), pp. 65–67. Basel: Karger 1970Google Scholar
  163. Vogel, G., Ther, L.: Das Verhalten der Baumwollratte zur Beurteilung der neuroleptischen Breite zentral-depressiver Stoffe. Arzneim. Forsch. 10, 806–808 (1960)Google Scholar
  164. Voith, K., Herr, F.: The behavioral pharmacology of butaclamol hydrochloride (Ay-23,028), a new potent neuroleptic drug. Psychopharmacologia 42, 11–20 (1975)PubMedGoogle Scholar
  165. Von Voigtländer, P.F., Moore, K.E.: Turning behavior of mice with unilateral 6-hydroxydopa-mine lesions in the striatum. Neuropharmacology 12, 451–463 (1973)Google Scholar
  166. Votava, Z.: Habituation and withdrawal symptoms after one week administration of perphenazine in rabbits. Psychopharmacologia 26, Suppl. 100, (1972)Google Scholar
  167. Walaszek, E.J., Abood, L.G.: Effect of tranquilizing drugs on fighting response of Siamese fighting fish. Science 124, 440–441 (1956)PubMedGoogle Scholar
  168. Wang, S.C.: Perphenazine, a potent and effective antiemetic. J. Pharmacol. Exp. Ther. 123, 306–310 (1958)PubMedGoogle Scholar
  169. Weese, H.: „Potenzierte Narkose” und „Hibernation durch Phenothiazine”. Arch. Exp. Pathol. Pharmakol. 222, 15–20 (1954)Google Scholar
  170. Weiss, B., Santelli, S.: Dyskinesias evoked in monkeys by weekly administration of haloperidol. Science 200, 799–801 (1978)PubMedGoogle Scholar
  171. Welch, B.L., Welch, A.S.: Aggression and the biogenic amine neurohumors. In: Aggressive Behavior. Garattini, S., Sigg, E.B. (eds.), pp. 188–202. Amsterdam: Excerpta Medica 1969Google Scholar
  172. Welch, B.L., Welch, A.S.: Some aspects of brain biochemistry correlated with general nervous reactivity and aggressiveness. In: Animal aggression: Selected readings. Southwick, C.H. (ed.), pp. 187–200. New York: Van Nostrand-Reinhold 1970Google Scholar
  173. Wickler, W.: Ökologie und Stammesgeschichte von Verhaltensweisen. Fortschr. Zool. 13, 303 – 365 (1961)PubMedGoogle Scholar
  174. Wilson, M.C., Schuster, C.R.: The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacologia 26, 115–126 (1972)PubMedGoogle Scholar
  175. Wirth, W., Gösswald, R., Hörlein, U., Risse, K.-H., Kreiskott, H.: Zur Pharmakologie acylier-ter Phenothiazin-Derivate. Arch. Int. Pharmacodyn. Thér. 115, 1–31 (1958)PubMedGoogle Scholar
  176. Yen, H.D.Y., Stanger, R.L., Millman, N.: Isolation-induced aggressive behavior in ataractic tests. J. Pharmacol. Exp. Ther. 122, 85 A (1958)Google Scholar
  177. Zetler, G.: Haloperidol catalepsy in grouped and isolated mice. Pharmacology 13, 526–532 (1975)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • H. Kreiskott

There are no affiliations available

Personalised recommendations